Kymera Therapeutics, Inc.
About Kymera Therapeutics, Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $39.2M
- Net income
- -$311.4M
- Total assets
- $1.7B
- Market cap
- $6.1B
- Gross margin
- 0.0%
- Operating margin
- -891.1%
- Net margin
- -794.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $39.2M
- Cost of revenue
- $39.2M
- Gross profit
- $0
- Operating expenses
- $388.6M
- Operating income
- -$349.4M
- Income tax
- $0
- Net income
- -$311.4M
- EPS (basic)
- $-3.69
- EPS (diluted)
- $-3.69
Balance sheet
- Total assets
- $1.7B
- Current assets
- $871.2M
- Total liabilities
- $163.1M
- Current liabilities
- $83.2M
- Shareholders’ equity
- $1.6B
Cash flow
- Operating cash flow
- -$232.9M
- Investing cash flow
- -$521.1M
- Financing cash flow
- $990.7M
- Net cash flow
- $236.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.1B
- EPS (diluted)
- $-3.69
- Shares outstanding
- 82.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 21, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $311.4M in FY2025.
- Revenue declined 46% from FY2021 to FY2025.
- Gross margin of 0.0%, net margin -794.0%.
- Trading 22% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Kymera Therapeutics, Inc..
Write a review
News about Kymera Therapeutics, Inc.
News & sentiment via Polygon.io
